Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Presenter: Robert Giugliano
Up Next
Presenter: Robin Hofmann
More slides +
Presenter: Borja Ibanez
Presenter: Jes Lindholt